Auxilium Pharmaceuticals, Inc. (Nasdaq:AUXL)

The price of AUXL stock jumped $2.31 (or +11.95%) to $21.64, and 7,434,821 of its shares exchanged hands on Friday’s market activity. On intraday trading, AUXL reached a new 52 week high of $22.00

AUXL reported that the U.S. FDA has approved XIAFLEX(R) (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie’s disease, a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the male genital..

AUXL‘s Xiaflex (collagenase clostridium histolyticum) is an enzyme that dissolves the plaque and, combined with physical therapy, can alleviate the curvature and associated symptoms.

Xiaflex is the first and only FDA-approved treatment proven effective for Peyronie’s disease in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.

It is estimated that as many as 9% of men have the condition – an embarrassing and sometimes painful curvature of the male genital. -, which can make intercourse painful or impossible.

The treatment will cost nearly $20,000 per patient, per year. Each injection of Xiaflex costs $3,300.

To support access to Xiaflex, AUXL has created Auxilium Advantage(TM) which is intended to provide a single point of contact for health care providers and patients for help accessing the product.

AUXL is a fully integrated specialty biopharmaceutical company with a focus on developing and commercializing products to predominantly specialist audiences.

More about Auxilium Pharmaceuticals, Inc. (Nasdaq:AUXL) at www.auxilium.com

**

 Crown Equity Holdings Inc. (CRWE)

Looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, CRWE is targeting the multi-billion dollar social networking community service market with its CRWE Network (CRWE-PR) project.

CRWE is currently developing a social networking service and phone app, CRWE Network (CRWE-PR), that is designed to target all the communities in every state of the United States.

CRWE Network will allow users to connect with people who live in their community.

CRWE Network‘s business plan is based on selling advertising to local businesses. Its goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums.

Community of Encinitas, CA, visit http://encinitas.crwe-pr.com and Get a CRWE Network Encinitas Site in Seconds for FREE

CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com.

**

ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP)

Shares of ZIOP climbed slightly $0.08 (or +2.07%) to $3.95, with a total volume of 877,720 shares on Friday’s trading session.

ZIOP reported positive interim results from its ongoing Phase 1/2 study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate that is being evaluated with the oral activator, veledimex, in patients with advanced melanoma.

In this study, 21 patients with unresectable, recurrent stage III/IV melanoma have been treated with intratumoral injections of Ad-RTS-IL-12 and the oral activator veledimex. The purpose of the study is to evaluate the safety and tolerability of the Ad-RTS-IL-12 and veledimex therapy, determine tumor and immune response, and select the optimal dose and schedule of veledimex for future study.

According to ZIOP, to date, this study has demonstrated immune response and encouraging activity, along with a tolerability profile that is well controlled by dose of the activator ligand veledimex. This should combine well with other emerging treatments to create a new treatment option for advanced melanoma and other cancers.

ZIOP is a biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer.

More about ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) at www.ziopharm.com.